$IDXX

IDEXX Laboratories reported Q2 2026 results driven by 10.3% organic growth in CAG Diagnostics recurring revenue, while U.S. same-store clinical visits fell 1.3%. Management raised full-year organic revenue growth guidance to 8.5% to 9.7% despite a $15 million FX headwind and expects U.S. visits to decline 1.5% in H2. Operating margin rose 110 bps.

IDEXX (NASDAQ:IDXX) highlighted Q2 results and product updates on its earnings call. VetLab consumables rose 14% organically, Global Reference Laboratory revenue grew over 10% organically, and Rapid Assay revenue returned to growth. IDEXX placed 5,265 premium instruments, including 1,602 inVue Dx analyzers, and raised 2026 revenue outlook to $4.70-$4.745B and EPS to $14.69-$14.94.

Investing.com reports IDEXX Laboratories shares rose 3.9% in pre-open after Q2 2026 results beat expectations. Adjusted EPS was $4.27 vs $3.96 consensus, and revenue was $1.22B vs $1.20B. The company raised and narrowed FY2026 guidance to EPS $14.69-$14.94 and revenue $4.70-$4.75B. U.S. equity futures were also higher.

IDEXX LABORATORIES INC /DE (IDXX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622041d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results ▪ Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. ▪ Strong vol

Bank of America said animal health stocks face continued 2Q26 pressure from fewer veterinary visits and higher drug competition. It kept Elanco Animal Health (Elanco) as its top pick with a buy rating, while maintaining neutral ratings on Zoetis and Idexx Laboratories. VetSource data showed Q2 visits down 1.9% YoY and July down 4% YoY. BofA expects FY2026 visits to fall about 2% and sees Elanco pricing rising below Zoetis.

UBS said Elanco Animal Health is its strongest animal health pick for Q2, citing US pet healthcare momentum through May and early market share gains for Credelio Quattro. UBS expects Q2 revenue above expectations and a potential full-year guidance raise, kept a buy rating and set a $31 price target versus $25.33. UBS was neutral on IDEXX and Zoetis.

Idexx Laboratories said May 26 it expanded its Fecal Dx antigen testing to detect taeniid tapeworm species (Taenia and Echinococcus). The company says the upgrade can identify up to twice as many infections earlier than fecal flotation and will be added automatically to U.S. and Canada panels starting late June at no extra cost. On May 19, it said SDMA will be integrated into Catalyst CLIPs in June.

IDEXX Laboratories (IDXX), a $44.3 billion veterinary diagnostics and software company, has underperformed the Nasdaq. Shares are down 27.1% from a 52-week high of $769.98 and down 7.8% over three months, versus the Nasdaq Composite’s 15.8% gain. The stock is down 17.1% in 2026 vs. NASX’s 11.6%. The article cites concerns over moderating companion animal growth and softer demand, plus FX and uneven international demand. Analysts rate it “Moderate Buy” (15 analysts) with a $731.54 mean price targ

Walter Public Investments Inc. bought a new stake in IDEXX Laboratories in Q4, purchasing 9,963 shares worth about $6.74 million, according to Holdings Channel.com. Other funds also adjusted positions. IDEXX reported Q earnings of $3.47 EPS on $1.14 billion revenue (above consensus) and set FY2026 guidance of 14.450–14.900 EPS. Analysts cited by the article cut targets.

The article says IDEXX Laboratories (IDXX) is embedding an early kidney disease detector into its most popular test profile. It also discusses broader AI expectations, citing Jeff Bezos, Andy Jassy, and Elon Musk’s 2040 humanoid-robot outlook, and mentions an “Insider Monkey” claim of a $3 stock with potential “400% upside,” plus prior BTI performance.